Vunakizumab

夫那奇珠单抗

Report date: 2024/12/06 10:55:04

Base Information

Drug NameVunakizumab
Drug Alias Name夫那奇珠单抗安达静SHR-1314
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionInterleukin 17A inhibitors
TargetsInterleukin 17A
Therapy Area/IndicationsPlaque psoriasisNon-radiographic axial spondyloarthritisAxial Spondyloarthritis +[11] 
Global Approved IndicationsPlaque psoriasis
Approved Indications in ChinaPlaque psoriasis
Original Approved Country/TerritoryMainland China
Original Approved Date2024/08/20
Country/TerritoryUnited StatesAustraliaMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesJiangsu Hengrui Medicine Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesSuzhou Suncadia Biopharmaceuticals Co Ltd
Inactive CompaniesAtridia Pty LtdShanghai Hengrui Pharmaceutical Co LtdJiangsu Hengrui Medicine Co Ltd
Active IndicationsPlaque psoriasisNon-radiographic axial spondyloarthritisLupus Nephritis +[6] 
Inactive IndicationsAxial SpondyloarthritisAutoimmune DiseasesPsoriasis +[5] 

Other Information

ATC CodeN/A
Related LinksDrugBank